

# **EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT™ CORONARY STENT IMPLANTATION, IN REAL-WORLD CLINICAL PRACTICE.**

**C. Graidis, G. Mamadas, D. Dimitriadis, A. Ntatsios, A.D. Maurogianni, V. Psifos,  
V. Karasavides, K. Stefanou, G. Spiromitros, G. Karakostas, D. Platogiannis.**

**Cardiology Department, Euromedica-Kyanous Stavros, Thessaloníki, Greece.**

**AICT 2010-Athens Interventional Cardiovascular  
Therapeutics XI**

**8-9 OCTOBER 2010**

**Divani Caravel Hotel, Athens**



**ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΚΑΡΔΙΑΓΓΕΙΑΚΩΝ ΝΟΣΗΜΑΤΩΝ**

# Aims

**To evaluate the safety and efficacy of the PROMUS Element™ stent system for the treatment of patients with de novo atherosclerotic coronary artery lesions. This everolimus-eluting stent is based on a platinum chromium platform and is being evaluated in the PLATINUM clinical trial.**



## Materials and Methods

**A total of 100 consecutive patients were identified, who underwent percutaneous coronary intervention with PROMUS Element™ stent implantation between December 2009 and April 2010.**

**The incidence of in-hospital and short-term Major Adverse Cardiac Event (death, myocardial infarction, target lesion revascularisation) rate was examined.**



## Baseline characteristics

<b>n</b>	<b>100</b>
<b><i>Clinical Characteristics</i></b>	
<b>Mean Age (years)</b>	<b>66 (Range: 42 to 90)</b>
<b>Men (%)</b>	<b>75</b>
<b>Diabetes Mellitus (%)</b>	<b>19</b>
<b>Hypertension (%)</b>	<b>66</b>
<b>Dyslipidemia (%)</b>	<b>42</b>
<b>Current smokers (%)</b>	<b>30</b>



### ***Indication for PCI***

**Acute Coronary Syndrome  
(%)**

**84**

**Stable Angina (%)**

**16**

### ***Angiographic characteristics***

**Bifurcation lesions**

**22**

**Total Occlusions**

**11**

**Previous PCI (%)**

**15**

**Previous CABG (%)**

**7**





## PCI Data

<b>Total Number of Stents implanted</b>	<b>232 (2.32±1.19 per patient)</b>
<b>Number of Vessels treated per patient (Average±StDev)</b>	<b>1.58±0.68</b>
<b>Number of Stents per lesion treated (Average±StDev)</b>	<b>1.21±0.52</b>
<b>Stent Diameter (mm)</b>	<b>Mean±StDev: 2.83±0.31 / Range: 2.25 to 4</b>
<b>Stent Length per patient (mm)</b>	<b>Mean±StDev: 51.6±26.2 / Range: 16 to 116</b>
<b>Direct Stenting (% of the cases)</b>	<b>40.6</b>
<b>Post - dilation (% of the cases)</b>	<b>91.5</b>



## **In-Hospital Clinical Outcomes**

**Procedural success rate: 100%**

- **In-hospital MACEs: 0**

## **Short-Term Clinical Outcomes**


**Clinical follow-up available in all patients with a mean duration of  $6.4 \pm 1.3$  months (range: 5 to 9 months).**

- **1 patient with a recent history of a large anterior MI died suddenly one month post-PCI and 1 patient died due to cerebrovascular accident.**
- **1 patient who received a stent in the mid-LAD, developed a new critical ostial LAD lesion 8 months after the index PCI and underwent CABG.**
- **No patients required target lesion revascularisation and there were no cases of myocardial infarction.**



# CASE 1


Coronary  
Angiography



Immediate  
Result



F/U 6 months



ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΚΑΡΔΙΑΓΓΕΙΑΚΩΝ ΝΟΣΗΜΑΤΩΝ




# CASE 2

Coronary  
Angiography



Immediate  
Result



F/U 6 months




# Conclusions

**Our initial experience with the PROMUS Element™ coronary stent system shows that it is safe and effective with an acceptable MACE rate at short term follow-up.**



[www.e-cardio.gr](http://www.e-cardio.gr)

Every week Complex coronary and cardiovascular cases and more



[www.e-cardio.gr](http://www.e-cardio.gr)

Please visit our website and register online.



ΕΛΛΗΝΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΚΑΡΔΙΑΓΓΕΙΑΚΩΝ ΝΟΣΗΜΑΤΩΝ